MDS Nordion Opens New Radiopharmaceutical Production Facility in Belgium
28 Mai 2009 - 2:00PM
PR Newswire (US)
OTTAWA, Canada and FLEURUS, Belgium, May 28 /PRNewswire-FirstCall/
-- - Site to Provide Fluorodeoxyglucose (F-18 FDG) for use in
Earlier Detection of Disease and Therapy Management MDS Nordion, a
leading global provider of medical isotopes and
radiopharmaceuticals used in molecular medicine, today announced
the opening of a facility in Fleurus, Belgium for the production of
Fluorodeoxyglucose (F-18 FDG), a radiopharmaceutical used in
positron emission tomography (PET) imaging. PET imaging produces a
three-dimensional image, or picture, of functional processes in the
body, such as brain activity, and is a highly accurate and
effective method of diagnosing disease and managing patient
therapy. MDS Nordion's new facility will provide timely supply of
F-18 FDG to hospitals throughout Belgium, France, The Netherlands,
Luxembourg and Germany. "Customers count on MDS Nordion for
leadership, quality products and customized services," said Steve
West, President MDS Nordion. "Our investment in this facility
further demonstrates our commitment to address the growing demand
for PET diagnostic imaging in targeted European regions, and
provides the medical community greater service for their future
patient care." The PET imaging market is the most rapidly growing
area of nuclear medicine and procedures. Statistics from a recent
Medical Options survey indicates PET examinations are on a rapid
rise in Europe, and are expected to grow at a compound annual rate
of approximately 20% through 2012. To help meet increasing demand,
this state-of-the-art, Good Manufacturing Practice (GMP) production
facility will have three daily production runs and a customer
service team available 24 hours a day, seven days a week. "PET
imaging is effective because it allows early detection of tumours,
as well as assessment of therapeutic strategies," said Professor
Roland Hustinx, Nuclear Medicine Department, CHU - Universite de
Liege. "In particular, MDS Nordion's new facility will provide
another source of supply of F-18 FDG to existing and new medical
facilities, thereby increasing the ability of health-care
practitioners to conduct this critical type of imaging." About MDS
Nordion MDS Nordion, a business unit of MDS Inc., is a global
leader in providing medical isotopes for molecular and diagnostic
imaging, radiotherapeutics and sterilization technologies for
medical products that benefit the lives of millions of people in
more than 50 countries around the world. MDS Nordion's products and
services are used on a daily basis by pharmaceutical and
biotechnology companies, medical-device manufacturers, hospitals,
clinics and research laboratories. Find out more at
http://www.mdsnordion.com/ About MDS MDS Inc. (TSX: MDS; NYSE: MDZ)
is a global life sciences company that provides market-leading
products and services that our customers need for the development
of drugs, and the diagnosis and treatment of disease. We are a
leading global provider of pharmaceutical contract research,
medical isotopes for molecular imaging, radiotherapeutics, and
analytical instruments. MDS has more than 5,000 highly skilled
people in 29 countries. Find out more at http://www.mdsinc.com/.
DATASOURCE: MDS CONTACT: CONTACT MDS Nordion: MEDIA: Shelley
Maclean, +1-613-291-3689, ; VPR Consult: Carl Bosteels,
+32-473-68-28-50, ; INVESTORS: Kim Lee, +1-416-213-4721,
Copyright